Adviser Investments LLC Has $1.09 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Adviser Investments LLC lowered its stake in Novo Nordisk A/S (NYSE:NVOGet Rating) by 1.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 9,734 shares of the company’s stock after selling 126 shares during the period. Adviser Investments LLC’s holdings in Novo Nordisk A/S were worth $1,085,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Farmers & Merchants Investments Inc. acquired a new stake in Novo Nordisk A/S in the first quarter valued at approximately $26,000. Cornerstone Advisory LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $28,000. Joseph P. Lucia & Associates LLC acquired a new stake in Novo Nordisk A/S in the first quarter valued at approximately $34,000. Worth Asset Management LLC acquired a new stake in Novo Nordisk A/S in the first quarter valued at approximately $32,000. Finally, Godsey & Gibb Associates acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 6.62% of the company’s stock.

Novo Nordisk A/S Trading Down 0.9 %

NVO opened at $98.31 on Friday. Novo Nordisk A/S has a 1-year low of $91.51 and a 1-year high of $122.16. The company has a current ratio of 0.94, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32. The company has a market cap of $222.47 billion, a P/E ratio of 29.35, a price-to-earnings-growth ratio of 1.77 and a beta of 0.47. The company has a fifty day moving average price of $107.60 and a two-hundred day moving average price of $109.28.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were paid a $0.5836 dividend. This represents a yield of 1.1%. The ex-dividend date of this dividend was Friday, August 12th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.18%.

Wall Street Analysts Forecast Growth

NVO has been the subject of several analyst reports. UBS Group downgraded shares of Novo Nordisk A/S from a “neutral” rating to a “sell” rating in a research note on Tuesday, June 28th. Guggenheim raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 31st. JPMorgan Chase & Co. raised shares of Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 7th. Exane BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a 750.00 price target for the company in a research note on Monday, June 27th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, July 15th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average target price of $682.43.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.